HAWTHORNE, N.Y.--(BUSINESS WIRE)-- Taro Pharmaceutical Industries Ltd. (NYS: TARO) ("Taro") reported today that it has received approval from the U.S. Food and Drug Administration ("FDA") for its New Drug Application ("NDA") Topicort® (desoximetasone) Topical Spray, 0.25%.

Topicort® (desoximetasone) Topical Spray, 0.25%is a corticosteroid indicated for the treatment of plaque psoriasis in patients 18 years of age or older.

According to industry sources, the corticosteroid spray market is approximately $100 million in annual sales in the U.S.

Taro Pharmaceutical Industries Ltd. is a multinational, science-based pharmaceutical company, dedicated to meeting the needs of its customers through the discovery, development, manufacturing and marketing of the highest quality healthcare products. For further information on Taro Pharmaceutical Industries Ltd., please visit Taro's website at www.taro.com.

Certain statements in this release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the Company's Topicort®(desoximetasone)Topical Spray, 0.25%. Although Taro believes the expectations reflected in such forward-looking statements to be based on reasonable assumptions, it can give no assurance that its expectations will be attained. Factors that could cause actual results to differ include industry and market conditions; slower than anticipated penetration of new markets; marketplace acceptance of Taro's Topicort®(desoximetasone) Topical Spray, 0.25%; changes in the Company's financial position; regulatory actions; and other risks detailed from time to time in the Company's SEC reports, including its Annual Reports on Form 20-F.Forward-looking statements speak only as of the date on which they are made. The Company undertakes no obligation to update, change or revise any forward-looking statements, whether as a result of new information, additional or subsequent developments or otherwise.